Medtronic Beats Q1 Estimates, Raises Forecast on Strong Segment Growth

Medtronic PLC (MDT) reported first-quarter financial results that exceeded Wall Street estimates and raised its full-year growth forecast, driven by strong performance across its major business segments. The company's performance was notably aided by an extra selling week during the quarter, a factor investors are watching closely as they assess underlying momentum.

Quarterly Performance Breakdown

Medtronic announced adjusted earnings per share of $1.45 on revenue of $9.80 billion for the first quarter. This compares favorably to consensus estimates, which projected an EPS of $1.39 on revenue of $9.55 billion, according to Investing.com.

Organic revenue grew by 13.7% year-over-year, but the company noted that the extra selling week contributed approximately 670 basis points to this figure. Excluding this calendar-related benefit, underlying growth was about 7%, which the source material described as the company's strongest performance in nearly eight years, outside of pandemic-era comparisons. Growth was broad-based across its divisions:

• Cardiovascular: Led the gains, with Cardiac Ablation Solutions growing 88% and Cardiac Rhythm Management increasing 15%.
• Neuroscience: Revenue rose 9.3%.
• Medical Surgical: Sales increased by 10.2%.
• Diabetes: The division posted organic growth of 14.9%.

Despite the strong revenue growth, adjusted operating margins expanded by only 10 basis points to 23.7%, indicating that top-line growth rather than operating leverage was the primary driver of the earnings beat.

Updated Guidance and Outlook

Ad

Following the strong quarter, Medtronic raised its fiscal 2027 organic growth guidance to a range of 7.25% to 7.75%, up from the previous 6.75% to 7.25%. The company also revised its full-year adjusted EPS forecast to $5.94–$6.00, a modest increase from its prior range.

However, the company's guidance for the upcoming second quarter suggests a more normalized growth rate. Medtronic projects Q2 organic growth of 6% and an adjusted EPS between $1.32 and $1.34. This earnings forecast trails the current analyst consensus of $1.35, setting up the next report as a key test of the company's momentum without the benefit of an extra week.

Catalysts and Analyst Views

Investors will be monitoring several upcoming catalysts, including the company's Investor Day scheduled for December 10-11, which could provide updates on long-term strategy and capital allocation. Medtronic also reiterated its commitment to completing the separation of its Diabetes (MiniMed) business before the end of the fiscal year.

Continued adoption of key products, such as the Hugo robotics system and new technologies in structural heart and renal denervation, remain central to its growth narrative. Following the report, analysts at BTIG raised their price target on Medtronic to $100, while TD Cowen maintained a $110 target, as cited by Investing.com.